{"name":"TransMedics","slug":"transmedics","ticker":"TMDX","exchange":"NASDAQ","domain":"transmedics.com","description":"TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ manag","hq":"Andover, MA","founded":0,"employees":"898","ceo":"Waleed Hassanein, M.D.","sector":"Medical Devices — Transplant","stockPrice":109.23,"stockChange":1.91,"stockChangePercent":1.78,"marketCap":"$3.7B","metrics":{"revenue":605494000,"revenueGrowth":32.2,"grossMargin":59.9,"rdSpend":69055000,"netIncome":190291000,"cash":488366016,"dividendYield":0,"peRatio":22.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"TransMedics reported revenue of $43.8 million for the fourth quarter and $143.8 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"TransMedics Announces Collaboration with University of California, San Francisco","summary":"TransMedics has entered into a collaboration with the University of California, San Francisco to develop new transplant technologies.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Clears TransMedics' Organ Care System for Ex Vivo Perfusion of Lungs","summary":"The FDA has cleared TransMedics' Organ Care System for ex vivo perfusion of lungs.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOeWR3X1RuNkpYczlNaHVZenhwVVlsUWFjcFJGeHZJSlhFRmdLNG9TdnlLV1pBaTN1WkhRQTdYM3FHbS1MVnBFdGpLZkVjTGlGcEFFdmRyV3FDcG1lb1dDMlE5RHhzOEhqZHVLQ2VEM25yRlpDaVFKVjE5R21TMHRXS0s0aldiWFlrRTAtOGlpenU3MXliLTN5MF94bThrdXMxcUhpeTZadWdid28xblloZXZrZlp1ZllHdkJ2dEk1T1ZtUjRYWVZUZVkyNlhPYjlkOVBIeGxBaUxtb2c?oc=5","date":"2026-04-03","type":"pipeline","source":"The Globe and Mail","summary":"Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail","headline":"Wall Street Analysts Are Bullish on Top Healthcare Picks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQM2xUQnh0aDhTY3FsdFl5MDJwWmdRSTRONG1kV2Z4SkF3TllnTmZqWS1GUEpVZnRUYW9OaU9Sa3hqS1ZvdURqRzh0YzZtcWNJRWhlMGhvdXRnbXlsSVRzMlN3VWNpdEQycy1mYXhnbU91b2hReWFvRGEtZEhCbWxHWGdtQWtGZ2h5eE93MFZfWWdNcVJacmdWd21YbEw?oc=5","date":"2026-03-09","type":"pipeline","source":"Seeking Alpha","summary":"TransMedics: Numb Reaction To Extraordinary Fundamentals (NASDAQ:TMDX) - Seeking Alpha","headline":"TransMedics: Numb Reaction To Extraordinary Fundamentals (NASDAQ:TMDX)","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPcG1uUUxITFpZQWM0YmpPbUY4LVZpT2pjTzRLZDZWdWc0YmE0bXVKb2l6X1Y5NEFsX0dPbmZBdGRaV2M5NHdqOXplRWpnWlFnNHQzczh1VWJCVF9fREV3cno2ZHl2VmVGeFhBZzlrd3BhUnNYVmtTVTVlSVVlNjBseFg2YnNlckZ1MkFDRHdrUlBEZ1M1ZWhuUkFDbHppZ1RyamZLSHk5NWdwVzg3WXh5ckktWXFTLWY0SFE?oc=5","date":"2026-01-12","type":"pipeline","source":"Stock Titan","summary":"New Somerville transplant tech hub could bring 600 good-paying jobs - Stock Titan","headline":"New Somerville transplant tech hub could bring 600 good-paying jobs","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxObjVqeE5SR2l1dXlmemlRYTFXX2pwZ0tjNTFBemZRWHEtQWNCQmxEQ256eWdnenJMdDhlRXFzQ1FFMk0ySFlNYXFvZTdCMkk3ZWpKQ1VnRW13SGtjRi1QQklJWTlqSHY2U002YkNtaFNGRWZCcF9Xb3FpSnN2WHJGajlBZ0FtcHd2REplVE9xb1FleUE5ZDFrTXVtekNwQ2p6Z3ZicUZDZzgtTmxLSUNTSW5CWnQtaFU?oc=5","date":"2026-01-09","type":"pipeline","source":"TradingView","summary":"3 MedTech Stocks That Crushed the S&P 500 Over the Past Year - TradingView","headline":"3 MedTech Stocks That Crushed the S&P 500 Over the Past Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOU1ZTSW1TdXNaOXJITWJ0MTlHOXdDRkVwR19zaTl2MV82SWNWeGxzb29LeEhPZ2hqYlhNVW5fYnpGVnY4c1VRZ1Q1VnVvNVcyQ3h1YnBmTUxLdkZ2V25FX092QVhNVHlpYU91ZF9Ta2QtcjMwR0pLU2d1VTJFZkhjTXZtY29xZw?oc=5","date":"2026-01-03","type":"pipeline","source":"Nanalyze","summary":"5 Biotech Stocks We Like in 2026. And 5 We Don’t - Nanalyze","headline":"5 Biotech Stocks We Like in 2026. And 5 We Don’t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVVVuVlpHSzd3UVJhNVp0NVpBYUVKTi0yNGlheTRYTDFmRjVab1hvazBjRW4zOE5UODBZZExQTjhLVnpSQTZla1NlMzJjanVnbGVDbXJ3TS16RHhhYXdpcmYtNFhmT1FJWThnaGhkQ1VfRF82VDJJWXNCdlNkSVlfQVBhSnRTNmlfbllYMHVlVDhkcGZGb1VQVENPN0k1V0VCR0hTcG9QTElPUmFGZXluVkR4TVJaZmtJdnBF?oc=5","date":"2025-12-24","type":"pipeline","source":"Stock Titan","summary":"New TransMedics hires get stock options and units with long vesting - Stock Titan","headline":"New TransMedics hires get stock options and units with long vesting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9jcnhIMDk3djRUT3ZZTjdqeWFoeldUelpVLVdmVGNsU0p1N2otU0ItSmJJTzJIb2xEaUhxLWttY3lTZzlwb1U0OVJBQjV5U0lJWnl5TnFjdk0tRi1tNmh0ZndoYUx5VEdNYUFDeTJheHpVbkphV2g4UkdkWQ?oc=5","date":"2025-12-09","type":"pipeline","source":"AOL.com","summary":"2 Under-the-Radar Stocks That Have Soared This Year - AOL.com","headline":"2 Under-the-Radar Stocks That Have Soared This Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE4xVEdySUsxMGJwMHdVQWtvUU9PbzZoc1N0bmtDc19PVER1M0IwVlo2NS1qRVVSNFRveWpOZDFVVkZ2Y09YYmlpSE9zZHY4amk5QS04UHIwV25jQzNMRGJ3TFprYWNtdkZnWF9Gb1ZqN0NLckFzeE0wem5ZdkluT3M?oc=5","date":"2025-12-01","type":"deal","source":"The Motley Fool","summary":"3 Top Stocks to Buy in December - The Motley Fool","headline":"3 Top Stocks to Buy in December","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQUF9hLVVFQWpKaTNDSWRLeUlhMmpORmNWeXYtczZSdmxsaVJveldVXzBkbDFpVk9TN0JJaFNNT0VpSlF1VE1OYXBlN1pCZVFtdXZudXNUcXNSRE1nMm9FcW9WV1cxNG0wUHdsMndVY3R1c3dUWl92enhmc3Z6b2xGVE5IZ3diWVN2dGkwSUNkZVlEdHR2UzZRRENPQlY0TU5KZDRuOW5vbTkzWk16RTdEQnB3X0w3dw?oc=5","date":"2025-11-18","type":"pipeline","source":"Stock Titan","summary":"TransMedics (Nasdaq: TMDX) to Host Fireside Chat at Piper Sandler 37th Conference - Stock Titan","headline":"TransMedics (Nasdaq: TMDX) to Host Fireside Chat at Piper Sandler 37th Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNTUp5UmZkY05IbWhGZlpvUVpFWDVqejZySmE0bHJVY2wtN1JLMHpXbG1TWEtPcE1KVzVkX0tEWjFlY1l1UVNCYnJkX2FiZ09aTVl5LVV5X0laZEJZbl9Zd2p3N3BIREI1aGNKbVRXTzQ5bEE1U25KUWxzTzcyREpmUnlkNm4?oc=5","date":"2025-09-22","type":"pipeline","source":"Seeking Alpha","summary":"TransMedics: I'm More Bullish Than Ever (NASDAQ:TMDX) - Seeking Alpha","headline":"TransMedics: I'm More Bullish Than Ever (NASDAQ:TMDX)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Xenios AG","OrganOx Limited","OCS International"],"therapeuticFocus":["Transplant Technology"],"financials":{"source":"sec_edgar","revenue":605494000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":605494000,"period":"2025-12-31"},{"value":441540000,"period":"2024-12-31"},{"value":441540000,"period":"2024-12-31"},{"value":241623000,"period":"2023-12-31"},{"value":241623000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":69055000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":190291000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1068373000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":109.23,"previousClose":107.32,"fiftyTwoWeekHigh":156,"fiftyTwoWeekLow":66.85,"fiftyTwoWeekRange":"66.85 - 156.0","fiftyDayAverage":126.97,"twoHundredDayAverage":124.09,"beta":2.08,"enterpriseValue":3712251136,"forwardPE":29.7,"priceToBook":7.91,"priceToSales":6.19,"enterpriseToRevenue":6.13,"enterpriseToEbitda":27.61,"pegRatio":0,"ebitda":134468000,"ebitdaMargin":22.2,"freeCashflow":94003624,"operatingCashflow":192840000,"totalDebt":519278016,"debtToEquity":109.8,"currentRatio":7.14,"returnOnAssets":7.2,"returnOnEquity":54.2,"analystRating":"1.5 - Buy","recommendationKey":"buy","numberOfAnalysts":10,"targetMeanPrice":156.1,"targetHighPrice":190,"targetLowPrice":118,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3,"institutionHeldPercent":111.3,"sharesOutstanding":34302451,"floatShares":33134110,"sharesShort":8330878,"shortRatio":8.97,"shortPercentOfFloat":24.3,"epsTrailing":4.87,"epsForward":3.68,"revenuePerShare":17.81,"bookValue":13.81,"officers":[{"age":57,"name":"Dr. Waleed H. Hassanein M.D.","title":"Founder, President, CEO & Director"},{"age":54,"name":"Mr. Gerardo  Hernandez","title":"CFO & Treasurer"},{"age":43,"name":"Mr. Nicholas  Corcoran","title":"Senior Vice President of Supply Chain & Operations"},{"age":56,"name":"Dr. Tamer I. Khayal M.D.","title":"Chief Commercial Officer"},{"age":43,"name":"Mr. Anil  Ranganath","title":"Advisor"},{"age":null,"name":"Mr. Matthew  Forsyth","title":"SVP, General Counsel & Corporate Secretary"},{"age":64,"name":"Ms. Miriam C. Provost Ph.D.","title":"Vice President of Global Regulatory Affairs"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.transmedics.com","phone":"978 552 0900"}}